BRAF融合在非小细胞肺癌中的研究进展

In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to...

Descripción completa

Detalles Bibliográficos
Autores principales: XIAO, Ping, ZHONG, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663773/
https://www.ncbi.nlm.nih.gov/pubmed/37989341
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.28
Descripción
Sumario:In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients.

Ejemplares similares